This study seeks to compare the treatment responses of Hodgkin and non-Hodgkin lymphoma patients using FDG PET/CT scans. 152 patients with histologically confirmed Hodgkin and non-Hodgkin lymphomas, who had undergone FDG PET/CT imaging for evaluating their treatment response after their initial chemotherapy regimen, were included in a retrospective study. The findings revealed that Hodgkin's lymphoma was more prevalent in females, and both types of lymphomas showed similar complete metabolic responses. However, Hodgkin's lymphoma demonstrated higher mild/high partial responses, and non-Hodgkin's lymphoma showed lower progressive metabolic disease.
Table of Contents
1. Introduction
1.1 Background of the Study:
1.2 Problem Statement
1.3 Justification
1.4 Study Objectives
1.5 Study Question
2. THEORY AND LITERATURE REVIEW
2.1 Introduction
2.2 lymphoma:
2.2.1 Hodgkin lymphoma
2.2.2 non-Hodgkin lymphomas
2.3 Symmetrical Study
3. Material and Methodology
3.1 Introduction
3.2 Study Design and Image Acquisition:
3.2.1 Ethical approval
3.2.2 Study population
3.2.3 Study sample size
3.2.4 data collection
3.2.5 inclusion and exclusion criteria
3.2.6 Study device and instruments
3.3 Data Analysis
3.3.1 FDG PET/CT image analysis
3.3.2 Statistical Analysis
4. RESULTS AND DISCUSSION
4.1 Introduction
4.2 Age, Gender, and Cancer Type Analysis
4.3 Gender-Based Distribution of Cancer Types an Analysis of Frequency and Percentages
4.4 study parameters
4.5 Percentage of Follow-up sessions between both cancers
4.6 The differences percentage between HL and NHL in the treatment provided
4.7 The Follow-up examination viability
4.8 Timing of the follow-up examination
4.9 Cancer Location
5. CONCLUSION AND RECOMMENDATIONS
5.1 Conclusion:
5.2 Recommendation:
5.3 Limitation:
Objectives & Research Scope
The primary aim of this study is to compare treatment responses in Hodgkin (HL) and non-Hodgkin lymphoma (NHL) patients by utilizing FDG PET/CT imaging as a central analytical tool within the Palestinian clinical context.
- Evaluation of FDG PET/CT efficacy in monitoring lymphoma treatment response.
- Comparison of treatment response patterns between HL and NHL patient demographics.
- Investigation of correlations between imaging findings and clinical outcomes.
- Development of evidence-based guidelines for routine PET/CT utilization in lymphoma management.
Excerpt from the Book
2.2.1.4.d FDG-PET/CT fusion
FDG-PET and CT provide functional and anatomic information, respectively. Integration of both modalities may outperform both FDG-PET alone and CT alone in staging of malignant lymphoma. In traditional visual image fusion, FDG-PET and CT images are viewed and compared next to each other, with the fusion taking place in the interpreter’s mind. Integration of separate FDG-PET and CT image sets into a single study can be achieved with software fusion.
However, differences in scanner bed profiles, external patient positioning, and internal organ movement present a challenge to the software approaches. These challenges have recently been addressed by the introduction of the combined PET/CT scanner, a hardware-oriented approach to image fusion. With this type of scanner, accurately registered anatomic and functional images can be acquired in a single examination, which has been shown to increase both the accuracy of the interpretation and the confidence level of the readers.
Several manufacturers are now offering integrated FDG-PET/CT systems combining different models of dedicated PET scanners and multidetector-row CT scanners in line with a common imaging bed. Patient preparation is similar to that of FDG-PET alone. It is important to apply an appropriate respiration protocol to minimize the mismatch between CT and FDG-PET. On completion of the CT portion of the examination, the patient couch is advanced into the PET field-of-view, and a multibed PET study is acquired over the same range as the CT scan. CT images are used for attenuation correction of the FDG-PET emission data. Again, both images with and without attenuation correction should be evaluated. There is no consensus yet whether intravenous and oral contrast materials are needed for a combined FDG-PET/CT examination.
Summary of Chapters
1. Introduction: Presents the global prevalence of lymphomas, the biological basis using DNA mutations, and outlines the critical need for improved treatment response monitoring.
2. THEORY AND LITERATURE REVIEW: Explores the clinical definitions, etiological factors, staging systems (Ann Arbor), and diagnostic imaging modalities (CT, MRI, PET) for Hodgkin and non-Hodgkin lymphoma.
3. Material and Methodology: Details the retrospective study design involving 152 patients, the imaging protocols at Al-Ahli Hospital, and the statistical methods used for result interpretation.
4. RESULTS AND DISCUSSION: Analyzes demographic distributions, treatment response intervals, follow-up session viability, and specific lesion locations in lymphoma patients.
5. CONCLUSION AND RECOMMENDATIONS: Summarizes the findings regarding treatment response differences and provides recommendations for longitudinal research and improved monitoring protocols.
Keywords
Hodgkin lymphoma, non-Hodgkin lymphoma, FDG PET/CT, treatment response, metabolic response, SUVmax, cancer staging, oncology imaging, patient follow-up, chemotherapy response, retrospective study, lymphoma diagnosis
Frequently Asked Questions
What is the core focus of this research?
The research focuses on evaluating the effectiveness of FDG PET/CT imaging in assessing and comparing treatment responses between Hodgkin and non-Hodgkin lymphoma patients.
Which key areas of oncology does this work address?
It covers lymphoma pathology, imaging diagnostics, treatment monitoring, and the prognostic value of PET/CT scanning in determining metabolic disease response.
What is the primary objective of this study?
To compare the treatment response rates and follow-up patterns of HL and NHL patients using PET/CT to identify the most effective monitoring strategies.
Which scientific methodology was utilized?
This study employed a retrospective analysis of 152 patients, utilizing descriptive statistics and Mann-Whitney tests to analyze treatment progress and PET imaging data.
What topics are discussed in the main chapters?
The chapters cover the clinical background, specialized literature review on lymphoma subtypes, research methodology, and a comparative discussion of results including follow-up outcomes.
What are the primary characteristics of this study?
It is defined by its retrospective nature, specific focus on FDG PET/CT modalities, and its context-specific application within the state of Palestine.
How does Hodgkin lymphoma typically compare to Non-Hodgkin lymphoma in this study?
The results indicate that HL tends to show more favorable metabolic response patterns in specific lung and nodal regions compared to NHL, which exhibits different recurrence profiles.
What is the suggested follow-up protocol for these patients?
The study proposes distinct follow-up timelines: 2–3 months for initial Hodgkin lymphoma visits, and 3–6 months for Non-Hodgkin lymphoma treatment monitoring.
- Quote paper
- Malik Ibrawish (Author), 2023, Comparative Analysis of Treatment Response in Hodgkin and Non-Hodgkin Lymphoma Patients Using FDG PET/CT Scans, Munich, GRIN Verlag, https://www.grin.com/document/1371435
